
Sign up to save your podcasts
Or


We discuss clinical trials using CNTF to treat MacTel Type 2 with Dr. John Pollack, Chief Medical Officer of Neurotech Pharmaceuticals.
By Retina Synthesis4.5
88 ratings
We discuss clinical trials using CNTF to treat MacTel Type 2 with Dr. John Pollack, Chief Medical Officer of Neurotech Pharmaceuticals.

43 Listeners

18 Listeners

99 Listeners

113,159 Listeners

56,945 Listeners

5 Listeners

9,560 Listeners

12 Listeners

47,707 Listeners

51 Listeners

11 Listeners

467 Listeners

19 Listeners

0 Listeners